ROLE OF ALECTINIB

by Rukhsar Sheikh Magicine Pharma - Life-saving medicine supplier

Alectinib is a novel FDA-approved, targeted therapy used to treat ALK(anaplastic lymphoma kinase)-positive advanced non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and is the leading cause of cancer-related deaths worldwide. ALK-positive NSCLC is a rare and aggressive form of lung cancer caused by a genetic abnormality in the ALK gene. Alectinib works by specifically targeting the cancer cells with the abnormal ALK gene, potentially providing a more personalized approach to treating NSCLC.

Dosage of alectinib administration

Alectinib is administered as a once-daily 150mg dose either orally or intravenously. It is combined with other drugs such as chemotherapy, immunotherapy, and other targeted therapies following the progression or recurrence of the disease. Alectinib has displayed superior efficacy in comparison to other existing ALK inhibitors such as crizotinib, with higher response and progression-free survival rates.

Side effects due to alectinib

Alectinib is generally well tolerated and has a balanced safety profile. Alectinib 150mg capsule side effects are- fatigue, diarrhea, musculoskeletal pain, and constipation. Due to its low toxicity and excellent safety profile, alectinib can be used in patients with mild to moderate renal impairment.

Approval for use in many countries

Alectinib is an effective and well-tolerated treatment for ALK-positive advanced NSCLC, providing an effective and safe strategy for these patients. It is currently approved for use in the United States, Europe, and Japan, and has recently been granted accelerated approval for use in patients with ALK-positive metastatic NSCLC in certain Asian countries.

Conclusion

Cap Alectinib 150mg has opened up a new era in the treatment of ALK-positive non-small cell lung cancer, providing a promising option for patients. This novel treatment strategy is expected to improve the lifespan and quality of life of those suffering from this rare and aggressive form of cancer. Alectinib provides hope for these patients and will likely be an important component of the cancer treatment continuum for many years to come.

read more